Portola Pharmaceuticals, Inc. was founded in 2003 and is headquartered in South San Francisco, Calif. We completed an initial public offering in May 2013 and are traded on the Nasdaq Stock Market under the symbol PTLA. We have approximately 95 employees.
Our goal is to build an enduring biopharmaceutical company with compounds from our own research efforts that represent significant advances in the fields of thrombosis and other hematologic diseases. Our development-stage portfolio includes three 100 percent-owned clinical-stage assets and one partnered program. Each of our therapies has the potential to address a significant unmet need.
We are advancing our three product candidates using novel biomarker and genetic approaches that may increase the likelihood of clinical, regulatory and commercial success of our first-in-class therapies.
- Betrixaban – an oral, once-daily Factor Xa inhibitor being studied in a biomarker-based Phase 3 study for hospital-to-home prophylaxis (preventive treatment) of venous thromboembolism (VTE) in acute medically ill patients (i.e., those hospitalized for medical conditions, such as heart failure, stroke, infection and pulmonary disease). Learn more.
- Andexanet alfa – a first-in-class recombinant, modified Factor Xa molecule that is being developed as an antidote for patients receiving a Factor Xa inhibitor who suffer a major bleeding episode or who may require emergency surgery. Andexanet alfa has been designated as a breakthrough therapy by the U.S. Food and Drug Administration. It is currently being evaluated in two pivotal Phase 3 studies with the Factor Xa inhibitors Eliquis® (apixaban) and XARELTO® (rivaroxaban) in healthy volunteers. Learn more.
- Cerdulatinib (PRT2070) – an oral, single-agent inhibitor of Syk and JAK pathways, which contribute to tumor cell growth and survival in certain hematologic malignancies. It is currently being evaluated in a Phase 1/2a study in chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma (NHL) patients. Learn more.